Search

GlaxoSmithKline PLC

Fermé

SecteurSoins de santé

1,788 1.85

Résumé

Variation du prix de l'action

24h

Actuel

Min

1742.5

Max

1790

Chiffres clés

By Trading Economics

Revenu

-126M

1.6B

Ventes

470M

8B

P/E

Moyenne du Secteur

19.759

37.003

BPA

0.47

Rendement du dividende

3.89

Marge bénéficiaire

20.611

Employés

68,629

EBITDA

139M

3.2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-5.15% downside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.89%

2.25%

Date du Prochain Dividende

8 janv. 2026

Date du Prochain Détachement de Dividende

13 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

10B

67B

Ouverture précédente

1786.15

Clôture précédente

1788

Sentiment de l'Actualité

By Acuity

33%

67%

71 / 373 Classement par Healthcare

GlaxoSmithKline PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 oct. 2025, 11:28 UTC

Résultats

GSK Lifts Guidance After Specialty Medicines Boost Sales -- Update

29 oct. 2025, 08:11 UTC

Résultats

GSK Raises Guidance After Sales, Earnings Growth

1 oct. 2025, 08:54 UTC

Principaux Mouvements du Marché

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

29 oct. 2025, 13:26 UTC

Market Talk
Résultats

GSK's Strong Results Likely to Bolster R&D Spending -- Market Talk

29 oct. 2025, 13:20 UTC

Market Talk

GSK Sales Growth, Pipeline Could Ease Skepticism of Ambitious Sales Goals -- Market Talk

29 oct. 2025, 12:26 UTC

Market Talk
Résultats

New GSK Chief to Inherit Healthy Business Despite Trade, Tariff Risks -- Market Talk

29 oct. 2025, 12:15 UTC

Market Talk
Résultats

GSK CEO Leaves Group in Good Health as Streamlining Pays off -- Market Talk

29 oct. 2025, 07:10 UTC

Résultats

GSK 3Q Adj EPS 55.0p

29 oct. 2025, 07:10 UTC

Résultats

GSK 3Q EPS 49.9p

29 oct. 2025, 07:09 UTC

Résultats

GSK Had Seen Core Operating Profit Growth of 6% to 8%

29 oct. 2025, 07:09 UTC

Résultats

GSK Now Sees Core Operating Profit Growth of 9% to 11%

29 oct. 2025, 07:08 UTC

Résultats

GSK Had Seen Core EPS Growth of 6% to 8%

29 oct. 2025, 07:08 UTC

Résultats

GSK Now Sees 2025 Core EPS Growth of 10% to 12%

29 oct. 2025, 07:06 UTC

Résultats

GSK Had Seen 2025 Sales Growth Toward Top End of 3% to 5% Range

29 oct. 2025, 07:06 UTC

Résultats

GSK Now Sees 2025 Sales Growth Between 6% to 7%

29 oct. 2025, 07:05 UTC

Résultats

GSK Raises 2025 View

29 oct. 2025, 07:02 UTC

Résultats

Analysts Had Seen GSK 3Q Core Operating Profit of GBP2.67B

29 oct. 2025, 07:02 UTC

Résultats

GSK 3Q Core Operating Profit GBP2.99B

29 oct. 2025, 07:01 UTC

Résultats

Analysts Had Seen GSK 3Q Sales of GBP8.24B

29 oct. 2025, 07:01 UTC

Résultats

GSK 3Q Sales GBP8.55B

29 oct. 2025, 07:00 UTC

Résultats

GSK PLC 3Q EPS 49.1p

29 oct. 2025, 07:00 UTC

Résultats

GSK PLC 3Q Adj EPS 55.0p

29 oct. 2025, 07:00 UTC

Résultats

GSK PLC 3Q Turnover GBP8.55B

29 oct. 2025, 07:00 UTC

Résultats

GSK PLC 3Q Pre-items, Pretax Pft GBP2.85B

29 oct. 2025, 07:00 UTC

Résultats

GSK PLC 3Q Pretax Pft GBP2.46B

29 oct. 2025, 07:00 UTC

Résultats

GSK PLC 3Q Oper Pft GBP2.59B

29 oct. 2025, 07:00 UTC

Résultats

GSK PLC 3Q Net Pft GBP2.01B

27 oct. 2025, 13:32 UTC

Résultats

GSK's Future Strategy in Focus Amid CEO Change -- Earnings Preview

1 oct. 2025, 07:53 UTC

Market Talk

Pfizer's U.S. Pricing Move Brings Clarity for Pharma Sector -- Market Talk

30 sept. 2025, 10:48 UTC

Market Talk

GSK's New CEO, Potential Vaccine Spinoff Signal a New Dawn -- Market Talk

GlaxoSmithKline PLC prévision

Objectif de Prix

By TipRanks

-5.15% baisse

Prévisions sur 12 Mois

Moyen 1,666.58 GBX  -5.15%

Haut 2,170 GBX

Bas 1,345 GBX

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

13 ratings

3

Achat

7

Maintien

3

Vente

Sentiment

By Acuity

71 / 373Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat